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It is now well established that B cells use two distinct receptors to respond to an antigen (i, 
2). One of these,  surface immunoglobulin receptors, recognize epitopes with high affinity and 
ensure  clonal selection  by the  antigen.  The other class  of receptors controls triggering and 
growth, and recognizes mitogenic moieties on thymus-independent antigens or T-cell derived 
helper factors in the response to thymus-dependent antigens (1). 
The genetic and structural characterization of mitogen receptors is very limited. So far, only 
the receptor for lipopolysaccharide has been studied in some detail, due to the availability of 
two mutant strains which appear to carry nonfunctional alleles  of the gene coding for that 
receptor (3-7)a Other ways of obtaining reagents specific for these types of receptors appear of 
great importance, for they are fundamental components of immune reactivity. 
We envisaged the possibility that simple molecules, such as polysaccharides, which 
display thymus independence and, therefore, direct mitogenicity for B cells, could be 
a  useful  tool  in  this  search.  Our  hypothesis  was  that  the  same  structure  in  these 
bifunctional molecules would be specifically recognized both by antibody combining 
sites  and  by polyclonally distributed  mitogen  receptors.  The possibility  could  exist 
that these two structures, recognizing the same simple determinant,  would be similar 
enough to cross-react when analyzed with an antibody. 
We chose to test  this possibility in the dextran B1355 system, where good reagents 
were available and where the genetics of the antibody counterpart were well studied 
(8, 9). The prediction was that an anti-idiotypic antibody, specific for dextran binding 
sites  on  antibody  molecules  would  also recognize the  mitogen  receptor  for dextran 
B1355, responsible for the polyclonal activation of B cells by dextran. 
In this paper we report experiments confirming this prediction,  and we start some 
elaboration on the significance of this finding. 
Materials  and Methods 
Anti-J558 idiotypic antisera  to the purified myeloma protein J558 (o.~.) with anti-dextran 
B1355 antibody activity was raised in A/He mice. Sera or ascites of BALB/c mice carrying the 
J558 tumor were immunoadsorbed onto a dextran B1355 polyacrylamide gel (10). A/He mice 
received weekly injections ofJ558 subcutaneously in the inguinal and axial node areas and in 
the hind  foot pads.  The antigen  was in  complete Freund's  adjuvant,  incomplete  Freund's 
adjuvant,  and  phosphate-buffered  saline  for  the  first,  second,  and  subsequent  injections, 
respectively. After four injections mice were assayed for anti-J558 activity by inhibition of  J558- 
dextran  B1355  hemagglutination  and  strong  sera  were  pooled.  The  antiserum  was  finally 
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absorbed on Sepharose-coupled normal mouse IgG and 19S fraction from normal mouse sera. 
Dextran B1355.  Fraction  S  from NRRL B1355 was a  kind  gift  from Dr.  Allene Jeanes, 
retired from Northern Regional Research Laboratory, U. S. Department of  Agriculture, Peoria, 
Ill. 
Immunofluorescence.  An Ig fraction of anti-J558 antiserum was prepared by repeated precip- 
itation with 1.6-M ammonium sulfate and labeled with trinitrophenylsulfonic acid (11). Rabbit 
antl-mouse #-chains, and goat anti-DNP antibodies were labeled with tetramethylrhodamine 
and fluorescein isothiocyanate, respectively (12). For the staining, spleen cells were incubated 
for 30 min in ice with the TNP-labeled anti-idiotypic antiserum in the presence of 5 ×  10  -4 M 
TNP-aminocaproic acid, washed thoroughly with balanced salt solution containing 10% fetal 
calf serum and 10 mM sodium azide and exposed to FITC-labeled anti-DNP antibodies, again 
for 30 min  in  the cold.  When double staining  was performed,  the cells  were  incubated  in 
TRITC-labeled  anti-mouse  #-antibodies,  either  before  or after  the  staining  with  the  anti- 
idiotypic antiserum. For redistribution studies, cells were exposed to the first reagent for 20 min 
in the cold and then for 10 rain at 37°C, washed in cold medium and exposed to the other 
reagents  strictly  in  the  cold  and  in  the  presence  of 20  mM  sodium  azide.  The  stained 
preparations were observed under fluorescence microscopes (Zeiss Photomikroskop II or Leitz 
Orthoplan) equipped with vertical illuminators and filter combinations specific for fluorescein 
and rhodamine. Total cells in the microscopic field were counted in phase contrast. 
Cell Cultures.  Cell cultures and reagents were as previously described (13). Briefly,  l0  s or 2 
×  l0  s cells were cultured in RPMI-1640 supplemented with glutamine antibiotics, Hepes, 2- 
mercaptoethanol  and  10%  fetal  calf serum  (Gibco  U155701D,  Gibco-Bio  Cult,  Glasgow, 
Scotland)  in  0.2-ml  aliquots  in  Microtiter  tissue  culture  plates.  Anti-idiotypic  antibodies, 
normal mouse serum, or dextran B1355 were titrated  in the cultures, and lipopolysaccharide 
(LPS),  kindly  provided  by Doctors C.  Galanos  and  O.  Luderitz,  Max-Planck  Institute  fiir 
Immunobiology, Freiburg, West Germany, was used as a control. The cultures were assayed at 
various incubation times for proliferation by measuring tritiated thymidine incorporation, and 
for  B-cell  maturation  to  immunoglobulin-secreting  cells,  by  counting  numbers  of plaque- 
forming cells (PFC) in the protein-A plaque assay (14). These tests were performed exactly as 
described before (5,  14). 
Results 
B-Cell Mitogenicity  of Dextran 1355.  The  thymus-independence  of the  antibody 
response to dextran B1355 was likely to be due, as postulated before (15) to the B-cell 
mitogenicity  of these  molecules.  We  have  purposely  tested  dextran  B1355  for  this 
property, because the low responsiveness of some mouse strains, such as C57BL/6 (8) 
could be due to lack of recognition of the a-l,3 determinants  either at the antibody 
level,  or  at  the  mitogen  receptor  level.  The  latter  appeared  unlikely,  since  high 
responsiveness  was  allotype  linked  and  antibody  low-responders  to  dextran  could 
develop  good  anti-hapten  responses  when  dextran  was  used  as  a  carrier  (10),  in 
contrast to the situations where the defect is at the mitogen receptor level (2). It was 
not  surprising  therefore,  to  find  that  both  BALB/c and  C57BL/6  mice,  high-  and 
low-responders to dextran, respectively, both developed good polyclonal responses to 
surprisingly  low concentrations of dextran  (Table I). We conclude that  both strains 
display  a  functional  mitogen  receptor  for dextran  B1355,  in  a  large  fraction  of all 
spleen  cells.  Although  frequency determinations  have  not  been  performed  yet,  the 
relative magnitude of the response, as compared to the response to LPS, would suggest 
that the dextran-sensitive B-cell subset is roughly three to five times smaller than the 
LPS-sensitive  B-cell  subset.  The  latter  has  recently  been  determined  by two  inde- 
pendent methods to be ~30% of all splenic B cells (16,  17). 
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TAnL~ I 
Polyclonal Response of BALB/c and C57BL/6 Spleen Cells to Dextran B1355 
Cell density  Culture 
No mitogen  LPS 10 ~g/ml  Dx 1355 5 ng/ml 
cpm X  PFC  cpm X  PFC  cpm x  PFC 
10  -3  10  -s  10  -3 
BALB/c 
C57BL/6 
BALB/c 
C57BL/6 
days 
2.5 ×  106/ml  2  12.6  236  100.6  7,830 
2.5 ×  106/ml  2  20.5  593  201.5  15,946 
18.7  1,392 
68.7  3,970 
5 x  105/ml  5  0.9  79  25.7  21,840  2.5  1,797 
5 x  105/ml  5  1.1  116  11.3  11,880  7.4  3,700 
TABLE II 
Sta,'ning of Spleen Cells  from Different Strains of Mice by Anti-J558 Idiotypic 
Antibodies 
/L  + Cells  Strain  % of total 
J558  ÷ Cells 
% of Total  % of #+ 
BALB/c  29.4  6.1  20.1 
24.3  4.9  20.2 
35.8  5.3  14.2 
22.2  4.0  18.0 
C57BL/6  50.1  7.9  15.6 
54.6  6.4  11.7 
33.9  4.9  14.5 
CBA/J  39.5  10.4  26.3 
42.4  6.0  14.2 
26.1  5.6  21.4 
DBA/2  37.0  13.7  37.2 
53.7  8.4  15.6 
33.6  5.6  16.7 
Note: presence ofJ558 cross-reacting  antigens on spleen cells has been tested 
also in individual animals of the following  strains: C3H/Tif, C3H/HeJ, Balb/ 
B, SJL, C3H.SW, A/J, AKR, C57BL/10Sn, C57BL/10Sc.Cr., C57BL/6-Iga, 
B10.BR. In these strains the values of J558 positive cells ranged between 2.6 
and 7.4 of total spleen cells, and from 4.7 to 24.8 of~  ÷ cells. 
receptor, polyclonally distributed in a  sizable fraction of splenic B cells of both high 
and low responder mice, we have directly tested the possibility outlined above, namely 
that  the  anti-J558  idiotype  could  in  fact  recognize  the  dextran-specific  mitogen 
receptor. As shown in Table II, this appears to be the case. A sizable fraction of splenic 
B  cells,  in average  from  10  to  20%  of all  splenic B  cells  from  both  BALB/c  and 
C57BL/6 (as well as several other strains) are stained by the anti-idiotype. 
To  prove  that  the  staining of  the  cells  was  actually  due  to  the  anti-idiotypic 
antibodies and not to other antibodies present in the antiserum, and was directed to 
a  molecule  involved in  the  binding of  dextran,  the  staining was  repeated  after 
absorption of the antiserum on  the J558  myeloma protein or with other myeloma 
proteins of the same class and type, or performed in the presence of B 1355 dextran or 
of the a-l,6 linked dextran B512. The results are reported in Table III. The staining 
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TABLE III 
Inhibition of the Staining of BALB/c and C57BL/6 Spleen Cells by Anti- 
J558 Idiotypic Antibodies 
Strain  Inhibitor  J-558 Positive  Inhibition 
cells 
BALB/c 
%  % 
None  5.4  -- 
Dx B1355.  1.2  78 
Dx B512  5.7  0 
J558  1.4  75 
MoPe 315+~  4.8  12 
RPC 20 
865 
C57BL/6  None  5.4  -- 
Dx 1355'  1.4  75 
Dx 512  5.7  0 
J-558  1.0l  82 
MoPe 315+~: 
RPC-20  5.1  6 
* Dextran  B 1355 and dextran B512 were present in the staining mixture at a 
concentration  of I mg/ml. Dextran  B1355 carries a-l,3 linkages to which 
J558 antibodies bind, while dextran B512 has only a-l,6 linkages and does 
not bind J558. 
:~j558  (eokl), MOPC 315  (ookn) and RPC-20 (ht) proteins were reacted with 
the anti-idiotype  antiserum for 3 h in the cold at a concentration of 2 mg/ml 
of undiluted serum 
whereas  it  was  unaffected  by other  myeloma  proteins  and  by  dextran  B512.  This 
proves that the staining we observed is not due to antibodies to a- or h-chains, and is 
in fact due to antibodies specific for the idiotypic determinants on the J558 molecule. 
Furthermore, the inhibition of the binding of anti-idiotypic antibodies in the presence 
of dextran  B1355  demonstrates  that  the  anti-J558  idiotype recognizes  a  dextran- 
specific receptor on the cell surface. 
The Dextran-Binding Receptor, Cross-Reactive with J558 Idiotype,  is not an Immunoglobulin 
Molecule.  As shown in Table II, all cells positively stained by the anti-J558 antibodies 
were  also  positive  for  surface  IgM,  regardless  of which  receptor  was  stained  first. 
There was, however, no positive correlation in the intensity of staining displayed by 
individual cells with  the two reagents.  In view of these results, it was  important  to 
exclude  the  possibility that  our  anti-idiotypic antiserum  contained  antibodies  to 
immunoglobulin iso- or allotypes. From the way the antiserum has been prepared, no 
such  antibodies should be expected except for the remote possibility of some antial- 
lotypic determinants  of the  IgA molecules.  Using immunodiffusion  techniques,  we 
have failed to detect in this antiserum antibodies to IgM, IgA, and all IgG subclasses, 
at  a  concentration  of the  antiserum  over  100  times higher  than  that  used  for cell 
staining. In spite of that, we have additionally absorbed the antiserum on Sepharose- 
coupled IgG and  a  19S fraction from  mouse serum,  as well as on  a  IgA (TEPC  15) 
and )~ (RPC20)  myeloma proteins, and we did not find any difference in the number 
or  intensity  of staining  of cells  detected  by  the  unabsorbed  versus  the  absorbed 
antiserum. Furthermore, as shown above, the activity of the antiserum was absorbed 
by the immunizing idiotype and not by other BALB/c a- or )~-chains. 866  MITOGEN RECEPTORS AND ANTIBODY  MOLECULES 
TABLE IV 
Interactions of IgM and J-558-Cross-Reactive Mitogen Receptor on the Surface 
of Resting B Cells 
I Reagent*  II ReagentS: 
Inhibition experiments§  Cells  with 
coincident 
cap as % of 
IgM Posi-  J-558 Posi-  cells  bearing 
tive cells  tive cells  both 
markers 
Anti-g  u  Anti-J558  48.8  7.1  20 
Anti-J558  Anti-g  38.9  8.3  6 t 
* Staining performed so as to allow redistribution (37°C without inhibitors). 
:1: Staining performed in the cold and in the presence of 20 mM NaNz. 
§ Inhibition experiments where cells were allowed to internalize the molecules 
detected by the first reagent before being exposed to the second one. 
][ Rabbit anti-TEPC  183. With another rabbit anti-/~ antiserum (anti-MOPC 
104E), some inhibition  and  redistribution  of the J558  determinants  was 
observed. This could be due in our opinion to the presence of  anti-"idiotypic" 
antibodies cross-reacting with J-558, since it is known (10) that MOPC-104E, 
a dextran  1,3 binder, has an idiotype cross-reacting  with J558. 
There is no reason to assume, on the other hand, that an anti-allotype to BALB/c 
would  react  with  C57BL/6  and  all  other  strains  tested,  nor  that  an  anti-a  chain 
allotype would react with  10-20% of the IgM positive splenic B ceils. Furthermore, it 
is not conceivable that Ig molecules on that large fraction of all B cells would carry 
the J558 idiotype and be dextran-binding. 
We have performed  inhibition  and  redistribution  experiments  to further  analyze 
the  nonimmunoglobulin  nature  of  the  J558  cross-reactive  membrane  structure. 
BALB/c  spleen  cells  were  stained  with  either  anti-/~  or  anti-J558  in  conditions  to 
induce  the  redistribution  ("capping")  of the  reacted  molecules,  and  then  counter- 
stained  with  the  alternative  reagent.  The  results  are  reported  in  Table  IV.  It  was 
found  that  redistribution  of IgM  does  not  affect  the J558-cross-reacting  structure, 
indicating  that  they are independent  molecules on the  B-cell surface.  On  the other 
hand,  redistribution  of the molecules  detected  by the anti-J558  idiotype antibodies 
co-caps  the surface  IgM on roughly two  thirds  of the  cells,  a  situation  that  closely 
parallels the one observed with the mitogen receptor for lipopolysaccharide (18). The 
latter finding also excludes the possibility that the anti-J558 idiotype antiserum could 
react  with  surface IgD, since IgM and,IgD "cap" independently  in  both  directions 
(18,  19). 
Finally, preliminary experiments  have demonstrated  the presence of cells positive 
for the J558-cross-reactive structure in  15 days old fetal liver in the complete absence 
of cells bearing surface immunoglobulins. 
Anti-Idiotypic Antibodies  to j558 are Polyclonal B-Cell Mitogens.  The final proof for the 
recognition of a  dextran-specific  mitogen receptor by anti-J558  idiotypic antibodies 
would  be  of a  functional  nature.  Thus,  we  have  shown  before  that  anti-mitogen 
receptor antibodies are mitogenic for the B cells expressing that receptor (6). Therefore, 
we have investigated the mitogenic properties of this anti-idiotypic antiserum. 
As shown in Fig.  1, anti-J558  induces a  strong polyclonal response in spleen  cells 
from  both  BALB/c  and  C57BL/6  strains.  Activation  results  in  proliferation  and A.  COUTINHO, L.  FORNI,  AND B.  BLOMBERG  867 
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Fro.  1.  [aH]Thymidine incorporation (A) and IgM PFC, (B) of C57BL/6 and BALB/c spleen 
cells cultured in the presence of anti-J558 idiotypic antiserum or normal mouse serum. Values are 
given per culture, and shown here are the peak responses, day 3 for C57BL/6 and day 2 for BALB/c. 
lgG PFC have been tested at day 6, and for the highest concentrations only: the values observed per 
culture were: C57BL/6 792 IgG PFC, BALB/c 532 IgG PFC. Background values were 12 and 22, 
respectively, and IgG PFC in LPS stimulated cultures 36 and 520, respectively. 
TABLE V 
Presence of  J-558-Cross-Reacting Structure on the Membrane of Dextran- 
Activated B Cells 
Mitogen in culture 
J-558 Positive  LPS-R Positive 
Blasts  Small cells  Blasts  Small cells 
%  % 
Dextran  71.7  <0.5  47.5  8.6 
B1355 
LPS  59.1  3.6  84.2  1.6 
Note: the original population had 6.4% cells reacting with a-J558. 
maturation of B  cells to high rate immunoglobulin secreting PFC of both the IgM 
and the IgG classes. The magnitude of the response is comparable to that observed 
with dextran B1355  itself and, in comparison with the LPS induced response, with 
the number of cells stained by the antiserum. 
It is highly probable that the cells responding to the anti-J558 antibodies are those 
that we can label with the antiserum. Furthermore, for our prediction to be correct, 
these should be the dextran-reactive B cells. We performed an experiment attempting 
to  test  this  possibility.  Small  cells  from  C57BL/6  spleen  were  purified  on  a  1-g 
gradient (20), and stimulated in culture with dextran B1355 or with LPS for 36 h. 
Thereafter, we scored the positivity for the J558-cross-reactive molecules of the blasts 
(mitogen-reactive cells) and of the cells which had remained small after that period 
of stimulation (mitogen-unreactive). The presence of the receptor for LPS  (17)  was 
checked as a control. Results shown in Table V  indicate that in fact the cells reactive 868  MITOGEN  RECEPTORS  AND  ANTIBODY  MOLECULES 
to dextran were those bearing the J558-cross-reactive structure.  Thus,  dextran-un- 
reactive cells (small cell fraction) are completely depleted of  J558-positive cells, while 
cells with this marker are enriched over 10 times among the dextran reactive blasts. 
Parallel cultures stimulated with LPS still showed J558-positive cells in the small cell 
fraction (LPS unreactive), although in a lower number than in the starting prepara- 
tion, indicating a  partial overlap among the B-cell subsets responding to these two 
mitogens. 
Discussion 
We conclude from the present experiments that  an anti-idiotypic antiserum to a 
dextran-binding myeloma protein recognizes the mitogen receptor for dextran on B 
cells. It should be made clear that such mitogenicity is not carried out through surface 
immunoglobulin receptors on B cells. Thus, although the biochemical characterization 
of this novel type of receptor is still in progress, several findings exclude the direct 
participation  of surface  immunoglobulins  in  the  polyclonal triggering observed in 
response to this anti-idiotype. The number of cells responding to the anti-idiotype, 
comparable to the number directly stained, are orders of magnitude above those that 
should be expected from an immunoglobulin idiotype-anti-idiotype interaction. Fur- 
thermore, these numbers parallel those observed in the response to dextran B1355 
itself, which is a  B-cell mitogen as all other thymus-independent antigens  (15), and 
which inhibits  the interaction of the anti-J558  idiotype with this large subset  of B 
cells. We have evidence (Table V) for the presence of the J558-idiotype-cross-reactive 
structure exclusively on the subset of cells responding to dextran as a  mitogen, and 
not on cells which are dextran-unreactive. In addition, the binding of the anti-idiotype 
was inhibited by the idiotype itself, and not by other immunoglobulin molecules of 
the same class and type, excluding that our antiserum was recognizing other immu- 
noglobulin determinants on the cell surface. The experiments on the redistribution of 
surface  IgM  and  the J558-cross-reactive mitogen  receptor, also  demonstrated  that 
these are  two  independent  structures on the  B-cell surface. Although we  have not 
performed direct experiments to test this possibility, it is also unlikely that stimulation 
takes place through surface Fc receptors, since we and  many others have failed to 
activate B cells by exposing them to immune complexes or nonaggregated IgG (21, 
22). Furthermore, the selectivity of the anti-idiotype for a subset of B cells also points 
against this possibility, since the vast majority of the splenic murine B cells display Fc 
receptors  (23).  Finally, there  is  no a  priori reason why dextran should  inhibit  Fc- 
t'eceptor binding as it does in the present experiments. 
Before the confirmation that the phenomenon here described also applies to other 
idiotype-anti-idiotype systems, general conclusions should be taken with care. How- 
ever, the same simple rule should, in principle, apply to all other anti-idiotypes to 
antibodies to other simple molecules like dextran, in which mitogenic moieties and 
antigenic determinants are structurally similar. Actually, recent results demonstrating 
interference of anti-idiotypic antibodies to anti-levan antibodies, with the anti-TNP 
response to TNP-levan support our suggestion (C.  Bona, personal communication). 
We are analyzing several other anti-idiotypes, namely anti-MOPC460,  anti-3129, 
and  anti-MOPC104E  myeloma proteins, as well as anti-idiotypes to anti-PVP and 
anti-streptococcal (A5A) antibodies (kindly provided by Doctors P. A. Cazenave, M. 
Cohn, K. Forsbeck, B. Andersson, and K. Eichmann) and the results so far obtained 
closely parallel the situation described here for the anti-J558 idiotype system. A.  COUTINHO,  L.  FORNI, AND B.  BLOMBERG  869 
On  the other hand,  the cross-reactivity between such a  mitogen receptor and an 
antibody idiotype of likely germ-line origin (24) suggests new ways of thinking. Thus, 
the possibility should be kept in mind that mitogen receptors are, in fact, encoded by 
primordial genes where from the germ-line V  genes were derived. The maintenance 
of the structural similarities that allow for the cross-reaction here observed throughout 
long periods of evolution, poses further requirements for the internal regulation of the 
immune system. 
Summary 
The  antibody  response  to  dextran  B1355  is  thymus  independent,  and  in  high 
responder  mice, over 90%  of the antibodies  carry the  idiotype of an a-1,3  binding 
myeloma protein (.1558). The present experiments demonstrate:  (a) dextran B 1355  is 
a B-cell mitogen both in a strain which carries the J558 idiotype on antibodies and in 
a low-responder strain which does not express that idiotype on antibodies to dextran; 
(b)  anti-idiotypic antibodies to J558 recognize a  dextran-speeific surface receptor on 
10-15% of all splenic B cells in those two strains as well as in all strains so far tested; 
(c)  as shown by inhibition  experiments such surface receptors cross-react with J558, 
and (d) anti-idiotypic antibodies are mitogenic for spleen cells of both strains resulting 
in B-cell proliferation and maturation to polyclonal antibody secretion. 
Note added in proof  Identical results  to those shown in this paper have been obtained by 
using immunoabsorbent purified anti-J558 idiotypic antibodies. 
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